Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

"Vaccines produced using our approach will need regular updates to address the challenges of rapid virus evolution and the potential emergence of new norovirus genotypes as predominant strains in ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

DEAR PEOPLE’S PHARMACY: Why don’t some medical professionals recognize norovirus more readily? My friend had vomiting with diarrhea, stomach cramps and fever. When she described her illness to ...

This vaccine is designed to protect against multiple norovirus genotypes by instructing cells to produce virus-like particles that stimulate an immune response without causing infection ...

“Since mRNA vaccines can pack more proteins into [their] unique designs—three in this case for multiple norovirus genotypes—we might just be on the precipice of a commercial norovirus ...

From September 1, 2024 through the end of December, health officials reported 56 norovirus outbreaks across the country, spanning 10 different genotypes, or strains. That included two outbreaks ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...